Literature DB >> 22707076

Pharmacology of myocardial calcium-handling.

Julia Vogler1, Lars Eckardt.   

Abstract

Disturbed myocardial calcium (Ca(+)) handling is one of the pathophysiologic hallmarks of cardiovascular diseases such as congestive heart failure, cardiac hypertrophy, and certain types of tachyarrhythmias. Pharmacologic treatment of these diseases thus focuses on restoring myocardial Ca(2+) homeostasis by interacting with Ca(2+)-dependent signaling pathways. In this article, we review the currently used pharmacologic agents that are able to restore or maintain myocardial Ca(2+) homeostasis and their mechanism of action as well as emerging new substances.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22707076     DOI： 10.1007/s10354-012-0108-x

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  19 in total

Review 1.  Mechanism of action of Ca2+ sensitizers--update 2001.

Authors:  M Endoh
Journal:  Cardiovasc Drugs Ther       Date:  2001-09       Impact factor: 3.727

Review 2.  Calcium channel blockers: an update.

Authors:  Mark J Eisenberg; Anya Brox; Alain N Bestawros
Journal:  Am J Med       Date:  2004-01-01       Impact factor: 4.965

Review 3.  [On the function of beta3-adrenoceptors in the human heart: signal transduction, inotropic effect and therapeutic prospects].

Authors:  Christian Pott; Dirk Steinritz; Andreas Napp; Wilhelm Bloch; Robert H G Schwinger; Klara Brixius
Journal:  Wien Med Wochenschr       Date:  2006-08

Review 4.  Overview of the clinical pharmacology of antiarrhythmic drugs.

Authors:  R L Woosley; C Funck-Brentano
Journal:  Am J Cardiol       Date:  1988-01-15       Impact factor: 2.778

5.  Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Christian van der Werf; Prince J Kannankeril; Frederic Sacher; Andrew D Krahn; Sami Viskin; Antoine Leenhardt; Wataru Shimizu; Naokata Sumitomo; Frank A Fish; Zahurul A Bhuiyan; Albert R Willems; Maurits J van der Veen; Hiroshi Watanabe; Julien Laborderie; Michel Haïssaguerre; Björn C Knollmann; Arthur A M Wilde
Journal:  J Am Coll Cardiol       Date:  2011-05-31       Impact factor: 24.094

6.  Differential effects of amiodarone and desethylamiodarone on calcium antagonist receptors.

Authors:  J A Wagner; H F Weisman; J H Levine; A M Snowman; S H Snyder
Journal:  J Cardiovasc Pharmacol       Date:  1990-03       Impact factor: 3.105

Review 7.  Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.

Authors:  Christian Pott; Dirk G Dechering; Florian Reinke; Adam Muszynski; Stephan Zellerhoff; Alex Bittner; Julia Köbe; Kristina Wasmer; Eric Schulze-Bahr; Gerold Mönnig; Stefan Kotthoff; Lars Eckardt
Journal:  Europace       Date:  2011-02-02       Impact factor: 5.214

8.  Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass.

Authors:  Fredrick A Hilliard; Derek S Steele; Derek Laver; Zhaokang Yang; Sylvain J Le Marchand; Nagesh Chopra; David W Piston; Sabine Huke; Björn C Knollmann
Journal:  J Mol Cell Cardiol       Date:  2009-10-14       Impact factor: 5.000

Review 9.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

Authors:  Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg
Journal:  Eur Heart J       Date:  2008-09-17       Impact factor: 29.983

Review 10.  β-Adrenergic blockers.

Authors:  William H Frishman; Elijah Saunders
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-08-08       Impact factor: 3.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.